The Allen Institute and BioMarin Pharmaceutical Inc. (BMRN) announced a collaboration today that will use technologies developed at the Allen Institute to create new gene therapies aimed at rare genetic diseases of the central nervous system. They did not disclose financial terms.
BioMarin will receive an exclusive license to each program for research, development and commercialization.
The Allen Institute for Brain Science, a division of the Allen Institute, has developed modified adeno-associated viruses, or AAVs, that have been engineered to impact specific classes of cells in the brain.
The company noted that scientists from BioMarin and the Allen Institute will collaborate to establish whether these novel AAVs can enable the creation of a new class of gene therapies displaying a higher level of precision to treat diseases of the central nervous system.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.